Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Safety evaluation of algae...final ppt jun

1.282 Aufrufe

Veröffentlicht am

  • Als Erste(r) kommentieren

Safety evaluation of algae...final ppt jun

  1. 1. ‘Safety Evaluation Of Microalgae In Rodents.’ Presented By; Mr. Sharad D.Khune (M. Pharm Sem-III) Guided by; Dr. A.D. Kshirsagar Associate and Head (Department of Pharmacology) Padm. Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune-411018
  2. 2. Introduction;  Toxicology- is a science of posions their source,chemical composition,action,test for detectionand antitodes  Toxicologists talk about the target of a toxicant, they are referring to the particular macromolecule, cell, organ or biochemical process that the toxicant disrupts.  The way the toxicant is able to disrupt that process is called the mechanisnm of action the toxicant. Not all toxicants are lethal. They may alsocause disease, tissue damage,genetic alterations, cancer, etc.
  3. 3. Continued….
  4. 4. Safety pharmacology-  Definition- Saftey pharmacology is defined as those studies that investigate the potential undesirable pharmacodynamic effects of substance on physiological functions in relation to exposure in theraputic range and above. On the basis of hierarchical systems of human body it is divided in three category; 1.Core battery 2. follow up study 3. Supplemental study.
  5. 5. Microalgae- Microalgae are prokaryotic or eukaryotic photosynthetic micro organism that grow rapidly and live in harsh conditions due to their unicellular or simple multicellular structure. Ex. eukaryotic microalgae is green algae Chlorophyta.
  6. 6. Literature survey;  The theraputic use of algae has a long history with records dating back to the chinese ‘Ben cao’ , ayurveda medicine and materia medica of Discurides (approx 70 AD)This use continues today.  The application of algae derived compounds in modern medicine is still limited,however in last 15 years compounds from microalgae such as caratenoids ,long chain poly unsaturated fatty acids ,proteins are sold as neutraceuticals.  for example spirulina plantesis is a good source of protein.
  7. 7. Algal pigments….
  8. 8. Continued……  Algae are proving to be a source of many potential new drug and bioactive molecules with diverse pharmacological activities.  Biological activities in algal natural compounds have wide effect such as antibacterial,antifungal,antiviral,and antioxidant activities.
  9. 9. Applications of algae..
  10. 10. Need of work……  Thus, as we have seen in literature survey there is need of more use and commercial applications of microalgae to satisfy the demands of increasing world population.  But, it is prime important to asses the pre-clinical evaluation of new test substance on rodents before practicized on humans.
  11. 11. Aim and objective… A] To Study single dose acute oral toxicity study of Microlagea; 1. Cladophora , 2. Spirogyra, 3. Sirogonium, 4. Chlorella , 5. Scendesmus , B] To Study repeated dose oral toxicity (28 days)of Microlagea; 1. Cladophora . C]To Study repeated dose oral toxicity (28 days)of Microlagea; 1. Spirogyra
  12. 12. Material and methods….. Collection of algal biomass Selection of laboratory animal Housing and diet of laboratory animal Acclimatization of laboratory animal Preparation of doses. Number of animals and dose levels. Procedure to be followed. Observations and interpretation of results.
  13. 13. Material and methods…….. A] study of single dose (14 Days) acute oral toxicity of algae and in rats.(OECD guidelines 423);  The acute oral toxicity of algae and will be performed according to OECD guidelines 423.  The dose of 2000 mg/kg will be administered in female rats. Control group will be administered with 1 ml/kg vehicle.  The effect of the extract on body weight and food water consumption of the test group will be done in comparison with the control group.  Various parameters such as body weight, Food and water consumption FOB will be determined on the 0th, 7th, 14th day and relative organ weight of the control and treated group will also be determined. (OECD guidelines, 423) Histopathology if available.
  14. 14. Material and method……. B] study of the sub-acute (28 days)oral toxicity of algae Cladophora ; (OECD guidelines, 407).  Depending on the submaximal dose from single dose oral acute toxicity different doses of the algae will be selected for sub acute oral toxicity study and administered to the test group. period.Both the male and female rat will be selected for the study.  Toxicity and mortality will be observed during the experimental period.  Physiological ,FOB parameters will be evaluated on 0th, 7th, 14th, 21st, 28th and 42ndday For control,test and reserved group.  Hematological, biochemical and Histopathology study will be carried to study the effect of the drug on the major organs. (OECD guidelines, 407).
  15. 15. Continued……… C] Study of the sub-acute (28 days)oral toxicity of algae Spirogyra; (OECD guidelines, 407).  Depending on the submaximal dose from single dose oral acute toxicity different doses of the algae will be selected for sub acute oral toxicity study and administered to the test group.Both the male and female rat will be selected for the study.  Toxicity and mortality will be observed during the experimental period.  Physiological ,FOB parameters will be evaluated on 0th, 7th, 14th, 21st, 28th and 42ndday For control,test and reserved group.  Hematological, biochemical and Histopathology study will be carried to study the effect of the drug on the major organs. (OECD guidelines, 407).
  16. 16. STATISTICAL ANALYSIS…..  Statistical analysis will be done by one way ANOVA followed by Dunnett’s test.  Data will be express as Mean ± SEM.
  17. 17. Hypothesis….  The aim of present work is to check the toxicity of algal species and If,they are toxic they will be discarded.  Depending on results If they are safe ,we can proceed further and use them as a animal feed, neutraceuticals, feed additives,pharmacologically active biomolecules and theraputic agents respectively.
  18. 18. Continued……..
  19. 19. REFERENCES……..  F.S.k .Barar Essentials of pharmacotherapeutics, Edition 5 th, page no 1  Satish kumar , CNS safety pharmacology, CRIPS vol. 8 no.1 ,2007  Teresam, et al microalgae for biodiesel production and other application.Renewable and sustainable energy review 14(2010)217-232  Sushil kumar etal , International journal of pharmcy and pharmaceutical sciences, vol 4, suppl. 2, 2012.  Michael borowitzka, pharmaceuticals from algae, journal of biotechnology.vol-2
  20. 20.  El–barky et al, characterisation of neutraceutical compound in blue green algae spirulina maxima, journal of medicinal plant and research , vol 2(10),page no 292-300, oct 2008  M salzar et al, subchronic toxicity study in mice fed spirulina maxima , journal of ethnopharmacology, 62(1998) 235- 241.  OECD Guideline for the testing of chemicals: Acute oral toxicity (2001); 423  OECD Guideline for the testing of chemicals: Repeated dose 28 day oral toxicity study in rodents (2008); 407

×